Seagen has entered into a collaboration and licensing agreement with Zai Lab for the development and commercialisation of Tivdak®(tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. Seagen is eligible to receive an upfront payment of US$30 M as well as development, regulatory and commercial milestone payments, and tiered royalties. Based on the 2020 co-commercialisation agreement with Genmab, all upfront, milestone payments, and royalties will also be shared 50/50 with Genmab